Effects of highly purified eicosapentaenoic acid on erythrocyte fatty acid composition and leukocyte and colonic mucosa leukotriene B4 production in children with ulcerative colitis

Journal of Pediatric Gastroenterology and Nutrition

Volumn 37, Issue 5, 2003, Pages 581-585

  Shimizu, Toshiaki ^a   Fujii, Tohru ^a   Suzuki, Ryuyo ^a   Igarashi, Jun ^a   Ohtsuka, Yoshikazu ^a   Nagata, Satoru ^a   Yamashiro, Yuichiro ^a  

^a JUNTENDO UNIVERSITY   (Japan)

Author keywords

Eicosapentaenoic acid; Leukotriene B4; n 3 Polyunsaturated fatty acid; Ulcerative colitis

Indexed keywords

ICOSAPENTAENOIC ACID; ICOSAPENTAENOIC ACID ETHYL ESTER; LEUKOTRIENE B4; OMEGA 3 FATTY ACID; PHOSPHOLIPID; DOCOSAHEXAENOIC ACID; DRUG DERIVATIVE; FATTY ACID; OMEGA 6 FATTY ACID;

ADOLESCENT; ARTICLE; CHILD; CLINICAL ARTICLE; COLON MUCOSA; ERYTHROCYTE; ERYTHROCYTE MEMBRANE; FEMALE; HISTOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; LEUKOCYTE; LIPID COMPOSITION; MALE; MEASUREMENT; PRIORITY JOURNAL; RECTUM MUCOSA; RELAPSE; REMISSION; ULCERATIVE COLITIS; BIOSYNTHESIS; BLOOD; CHEMISTRY; COLON; INTESTINE MUCOSA; METABOLISM; RECURRENT DISEASE;

ADOLESCENT; CHILD; COLITIS, ULCERATIVE; COLON; DOCOSAHEXAENOIC ACIDS; EICOSAPENTAENOIC ACID; ERYTHROCYTE MEMBRANE; FATTY ACIDS; FATTY ACIDS, OMEGA-6; FEMALE; HUMANS; INTESTINAL MUCOSA; LEUKOCYTES; LEUKOTRIENE B4; MALE; PHOSPHOLIPIDS; RECURRENCE;

EID: 1542389412     PISSN: 02772116     EISSN: None     Source Type: Journal    
DOI: 10.1097/00005176-200311000-00015     Document Type: Article

References (28)

1. Lorenz R, Weber PC, Szimnau P, et al. Supplementation with n-3 fatty acids from fish oil in chronic inflammatory bowel disease: a randomized, placebo-controlled, double-blind cross-over trial. J Intern Med 1989;225(Suppl):225-32.
2. McCall TB, O'Leary D, Bloomfield J, et al. Therapeutic potential of fish oil in the treatment of ulcerative colitis. Aliment Pharmacol Ther 1989;3:415-24.
3. Hawthorne AB, Daneshmend TK, Hawkey CJ, et al. Treatment of ulcerative colitis with fish oil supplementation: a prospective 12 month randomised controlled trial. Gut 1992;33:922-8.
4. Aslan A, Triadafilopoulos G. Fish oil fatty acid supplementation in active ulcerative colitis: a double-blind, placebo-controlled, cross-over study. Am J Gastroenterol 1992;87:432-7.
5. Loeschke K, Ueberschaer B, Pietsch A, et al. n-3 fatty acids only delay early relapse of ulcerative colitis in remission. Dig Dis Sci 1996;41:2087-94.
6. 4 by colonic mucosa in inflammatory bowel disease. Gastroenterology 1984;86:453-60.
7. Casellas F, Papo M, Guarner F, et al. Effects of thromboxane synthase inhibition on in vivo release of inflammatory mediators in chronic ulcerative colitis. Eur J Gastroenterol Hepatol 1995;7: 221-6.
8. Almallah YZ, El-Tahir A, Heys SD, et al. Distal procto-colitis and n-3 polyunsaturated fatty acids: the mechanism(s) of natural cytotoxicity inhibition. Eur J Clin Invest 2000;30:58-65.
9. Belluzzi A, Boschi S, Brignola C, et al. Polyunsaturated fatty acids and inflammatory bowel disease. Am J Clin Nutr 2000;71(1 Suppl):339S-42S.
10. Shimizu H, Ohtani K, Tanaka Y, et al. Long-term effect of eicosapentaenoic acid ethyl (EPA-E) on albuminuria of non-insulin dependent diabetic patients. Diabetes Res Clin Pract 1995;28:35-40.
11. Kurabayashi T, Okada M, Tanaka K. Eicosapentaenoic acid effect on hyperlipidemia in menopausal Japanese women. The Niigata Epadel Study Group. Obstet Gynecol 2000;96:521-8.
12. Makino M, Oda N, Miura N, et al. Effect of eicosapentaenoic acid ethyl ester on hypothyroid function. J Endocrinol 2001;171:259-65.
13. Fisher SE. Nutritional therapy of chronic ulcerative colitis. J Pediatr Gastroenterol Nutr 1993;16:224.
14. Gomes P, du Boulay C, Smith CL, et al. Relationship between disease activity indices and colonoscopic findings in patients with colonic inflammatory bowel disease. Gut 1986;27:92-5.
15. Folch J, Lees M, Sloane Stanly GH. A simple method for the isolation and purification of total lipids from animal tissues. J Biol Chem 1957;226:497-509.
16. Chapkin RS, Haberstroh B, Liu T, et al. Characterization of the individual phospholipids and their fatty acids in serum and high-density lipoprotein of the renal patient on long-term maintenance hemodialysis. J Lab Clin Med 1983;101:726-35.
17. Odlander B, Claesson HE. A rapid and sensitive method for measurement of leukotrienes based on HPLC. Biomed Chromatogr 1987;2:145-7.
18. 4 generation by small intestinal mucosa in children with coeliac disease. Digestion 1994;55:239-42.
19. Lowry OH, Rosenbrough NJ, Farr AL, et al. Protein measurement with the folin phenol reagent. J Biol Chem 1951;193:265-75.
20. Samuelsson B, Dahlen S-E, Lindgren JA, et al. Leukotrienes and lipoxins: structures, biosynthesis, and biological effects. Science 1987;237:1171-6.
21. 4 release by rectal mucosa in active ulcerative colitis. Aliment Pharmacol Ther 1992;6:163-8.
22. 4 receptor antagonist SC-41930 on colonic inflammation in rat, guinea pig and rabbit. J Pharmacol Exp Ther 1990;255:572-6.
23. James MJ, Gibson RA, Cleland LG. Dietary polyunsaturated fatty acids and inflammatory mediator production. Am J Clin Nutr 2000;71(1 Suppl):343S-8S.
24. Saku N, Kobayashi J, Kitamura S. Eicosapentaenoic acid modulates arachidonic acid metabolism in rat alveolar macrophages activated by silica. Prostaglandins Leukot Essent Fatty Acids 1999; 61:51-4.
25. Nieto N, Torres MI, Rios A, et al. Dietary polyunsaturated fatty acids improve histological and biochemical alterations in rats with experimental ulcerative colitis. J Nutr 2002;132:11-9.
26. 2 production but have different effects on lymphocyte functions and cell-mediated immunity. Lipids 1998:33:171-80.
27. Kinsella JE. Dietary n-3 polyunsaturated fatty acids of fish oils, autoxidation ex vivo and peroxidation in vivo: implications. In: Friedman M, ed. Nutritional and Toxicological Consequences of Food Processing. New York: Plenum Press; 1991:225-68.
28. Krawisz JE, Sharon P, Stenson WF. Quantitative assay for acute intestinal inflammation based on myeloperoxidase activity. Assessment inflammation in rat and hamster models. Gastroenterology 1984;87:1344-50.